What is a broad-spectrum antibiotic for cellulitis?

Broad-Spectrum Antibiotic for Cellulitis

For outpatient cellulitis requiring broad-spectrum coverage (both streptococci and MRSA), use clindamycin 300-450 mg PO three times daily or linezolid 600 mg PO twice daily as monotherapy, or combine TMP-SMX/doxycycline with amoxicillin. 1

Clinical Decision Algorithm

Step 1: Classify the Cellulitis Type

Nonpurulent cellulitis (no drainage, no abscess):

• First-line: β-lactam alone (cephalexin 500 mg QID) targets β-hemolytic streptococci 1, 2
• Add MRSA coverage if: systemic toxicity present OR no response to β-lactam after 48-72 hours 1

Purulent cellulitis (drainage/exudate without drainable abscess):

• Empiric MRSA coverage required - streptococcal coverage likely unnecessary 1

Step 2: Choose Appropriate Broad-Spectrum Regimen

When you need coverage for both streptococci AND MRSA, the IDSA guidelines provide three evidence-based options 1, 2:

Single-agent options:

• Clindamycin 300-450 mg PO TID (A-II evidence) - covers both pathogens naturally
• Linezolid 600 mg PO BID (A-II evidence) - covers both pathogens naturally

Combination therapy:

• TMP-SMX 1-2 DS tablets BID PLUS amoxicillin 500 mg TID (A-II evidence)
• Doxycycline 100 mg BID PLUS amoxicillin 500 mg TID (A-II evidence)

Step 3: Consider Patient-Specific Factors

Clindamycin caveats:

• Higher risk of C. difficile infection compared to other oral agents 1
• Only use if local clindamycin resistance <10% 1
• Check for inducible resistance in serious infections

TMP-SMX restrictions:

• Avoid in third trimester pregnancy (Category C/D) 1
• Avoid in infants <2 months 1
• Risk of hyperkalemia in elderly, especially with renal insufficiency or ACE inhibitors 1

Tetracyclines (doxycycline/minocycline):

• Contraindicated in children <8 years 1
• Pregnancy Category D 1

Linezolid:

• Most expensive option but no resistance concerns 1
• Useful when other options contraindicated

Step 4: Duration and Monitoring

• Treatment duration: 5-10 days based on clinical response 1, 3
• Extend if no improvement within 5 days 3

Hospitalized Patients with Complicated SSTI

For severe cellulitis requiring hospitalization, IV vancomycin 15-20 mg/kg every 8-12 hours remains first-line (A-I evidence) 1. Alternative IV options include:

• Linezolid 600 mg IV BID (A-I)
• Daptomycin 4 mg/kg IV daily (A-I)
• Telavancin 10 mg/kg IV daily (A-I)

For severe infections with systemic toxicity, vancomycin PLUS piperacillin-tazobactam or a carbapenem provides appropriate broad-spectrum coverage 3.

Key Clinical Pitfalls

Avoid these common errors:

• Using TMP-SMX or tetracyclines alone for nonpurulent cellulitis - they lack reliable streptococcal coverage 1
• Using rifampin as monotherapy or adjunctive therapy - not recommended (A-III) 1
• Prescribing broad-spectrum antibiotics for simple nonpurulent cellulitis without risk factors - β-lactam monotherapy suffices 4

The evidence strongly supports that in MRSA-prevalent areas (>60% of S. aureus isolates), antibiotics with MRSA activity significantly reduce treatment failure (adjusted OR 4.22 for failure without MRSA coverage) 5. However, this applies primarily to purulent cellulitis or when specific risk factors exist (penetrating trauma, known MRSA colonization, injection drug use, systemic toxicity) 3.

Pediatric Dosing

• Clindamycin: 10-13 mg/kg/dose PO every 6-8 hours (max 40 mg/kg/day) 1
• TMP-SMX: Trimethoprim 4-6 mg/kg/dose every 12 hours 1
• Linezolid: 10 mg/kg/dose every 8 hours if <12 years; 600 mg BID if ≥12 years 1